OMGA Omega Therapeutics
- 2.305
- -0.055-2.33%
Omega Therapeutics News
Stocks With More Than 10% Short Interest - Finviz Screener
HC Wainwright & Co. : The Omega Therapeutics (OMGA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
HC Wainwright & Co. : The Omega Therapeutics (OMGA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
HC Wainwright & Co. Reiterates Buy on Omega Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics with a Buy and maintains $12 price target.
Buy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial Performance
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Omega Therapeutics Announced Presentation Of New Preclinical Data Demonstrating Durable, Tunable Bidirectional Regulation Of Gene Expression In Cellular Models At Pre-transcriptional Level At The American Society Of Gene And Cell Therapy Annual Meeting
Omega Therapeutics Announced Presentation Of New Preclinical Data Demonstrating Durable, Tunable Bidirectional Regulation Of Gene Expression In Cellular Models At Pre-transcriptional Level At The Amer
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression With Epigenomic Controllers
Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanismsAdditional OMEGA platform capabilities de
Analysts' Top Healthcare Picks: Fresenius Medical Care AG & Co. KGaA (GB:0H9X), Omega Therapeutics (OMGA)
4 Analysts Have This To Say About Omega Therapeutics
Ratings for Omega Therapeutics (NASDAQ:OMGA) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below provides a concise overview of r
Omega Therapeutics Is Maintained at Buy by Chardan Capital
Omega Therapeutics Is Maintained at Buy by Chardan Capital
Chardan Capital: Maintains Omega Therapeutics (OMGA.US) rating, adjusted from buy to buy rating, and adjusted target price from $7.00 to $7.00.
Chardan Capital: Maintains Omega Therapeutics (OMGA.US) rating, adjusted from buy to buy rating, and adjusted target price from $7.00 to $7.00.
Chardan Capital Maintains Buy on Omega Therapeutics, Maintains $7 Price Target
Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $7 price target.
Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
Buy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical Trials
Omega Therapeutics Q1 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate, Sales $2.360M Beat $1.630M Estimate
Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. The company reported quarterly sales of $2.360
Omega Therapeutics | 10-Q: Quarterly report
Omega Therapeutics: Runway To Fund Operations Into 1Q 2025 >OMGA
Omega Therapeutics: Runway To Fund Operations Into 1Q 2025 >OMGA
Press Release: Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress -- Advanced MYCHELANGELO(TM) I trial dose escalation to Cohort 5; Presentation of addit
Omega Therapeutics 1Q Loss $20.1M >OMGA
Omega Therapeutics 1Q Loss $20.1M >OMGA
Omega Therapeutics 1Q Rev $2.36M >OMGA
Omega Therapeutics 1Q Rev $2.36M >OMGA
Analysis
Price Target
No Data
